Stay updated with breaking news from Ellodi Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Despite being recognized as a distinct etiology of eosinophilic gastrointestinal disease for less than 30 years, EoE care has evolved to...
/PRNewswire/ -- DelveInsight's 'Eosinophilic Esophagitis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and...
In a phase 3 trial of adults and adolescents with hard-to-treat eosinophilic esophagitis, 6 months of weekly dupilumab sent 59% of participants into disease remission.